Asset profile
CAB-AXL-ADC
Unknown / undisclosed
Evidence outlook · lead readout
NCT04681131 · Non-Small-Cell Lung Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04681131: The study was nonrandomized and open-label, with two experimental treatment groups and no placebo or active comparator. Its primary efficacy endpoint was objective tumor response assessed by RECIST, but results are not posted, so the endpoint outcome cannot be evaluated.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.